said first-quarter earnings rose 58% to $713 million, or 79 cents a share, from $451 million, or 51 cents, a year earlier, on strong sales of multiple sclerosis drug Copaxone.
On an adjusted basis, first-quarter earnings were 91 cents a share; analysts surveyed by Thomson Reuters expected earnings of 89 cents.
Teva, the biggest generic drugmaker, said sales rose 16% to $3.7 billion, in line with the estimates of analysts.
Teva said sales of Copaxone, the leading therapy for multiple sclerosis, rose 28% to a record $796 million.
In March, Teva Pharmaceutical
agreed to buy Germany's second largest generics producer
for about $4.9 billion.
-- Reported by Joseph Woelfel in New York.
Follow TheStreet.com on
and become a fan on